Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $179 | $117 | $120 | $149 |
| % Growth | 53.4% | -2.8% | -19.4% | – |
| Cost of Goods Sold | $19 | $7 | $2 | $1 |
| Gross Profit | $161 | $110 | $118 | $148 |
| % Margin | 89.6% | 93.9% | 98.5% | 99.3% |
| R&D Expenses | $23 | $25 | $60 | $65 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $113 | $106 | $112 | $92 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $1 | $4 |
| Operating Expenses | $136 | $130 | $174 | $161 |
| Operating Income | $24 | -$20 | -$56 | -$12 |
| % Margin | 13.5% | -17.5% | -46.2% | -8.4% |
| Other Income/Exp. Net | -$6 | -$5 | -$3 | -$5 |
| Pre-Tax Income | $18 | -$25 | -$59 | -$17 |
| Tax Expense | $1 | $0 | $0 | $1 |
| Net Income | $17 | -$25 | -$59 | -$18 |
| % Margin | 9.8% | -21.5% | -48.7% | -12% |
| EPS | 0.99 | -1.44 | -3.4 | -1.1 |
| % Growth | 168.7% | 57.6% | -209.1% | – |
| EPS Diluted | 0.99 | -1.44 | -3.4 | -1.1 |
| Weighted Avg Shares Out | 18 | 17 | 17 | 17 |
| Weighted Avg Shares Out Dil | 18 | 17 | 17 | 17 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $1 | $0 |
| Interest Expense | $8 | $7 | $4 | $5 |
| Depreciation & Amortization | $2 | $1 | $1 | $1 |
| EBITDA | $29 | -$17 | -$54 | -$11 |
| % Margin | 15.9% | -14.5% | -44.8% | -7.6% |